New-York based financial services professional, Norman Gretzinger cofounded private equity firm EG Capital Group, LLC, in 2003, after spending seven years as the head of North American mergers and acquisitions for JP Morgan Chase. Norm Gretzinger supports charitable organizations such as the JDRF Diabetes Foundation and is an observer on the board of OncoPep, Inc., a company that develops targeted immunotherapeutics to prevent the progression of cancer.
Founded in 2010, OncoPep strives to develop technologies that prolong survival and improve quality of life for cancer patients. The company’s proprietary technology, developed by Dr. Kenneth Anderson at the Dana Farber Cancer Institute, has been used to create a therapeutic cancer vaccine that stimulates the patient’s immune system. The company’s lead program, PVX-410, utilizes several proprietary peptides that target antigens found on the surface of multiple myeloma (MM) cancer cells. The treatment specifically targets smoldering multiple myeloma, a precursor to MM for which there is no approved treatment.
Founded in 2010, OncoPep strives to develop technologies that prolong survival and improve quality of life for cancer patients. The company’s proprietary technology, developed by Dr. Kenneth Anderson at the Dana Farber Cancer Institute, has been used to create a therapeutic cancer vaccine that stimulates the patient’s immune system. The company’s lead program, PVX-410, utilizes several proprietary peptides that target antigens found on the surface of multiple myeloma (MM) cancer cells. The treatment specifically targets smoldering multiple myeloma, a precursor to MM for which there is no approved treatment.